List of Tables
    Table 1. Drugs for Non-Small Cell Lung Cancer Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Drugs for Non-Small Cell Lung Cancer Market Trends
    Table 3. Drugs for Non-Small Cell Lung Cancer Market Drivers
    Table 4. Drugs for Non-Small Cell Lung Cancer Market Challenges
    Table 5. Drugs for Non-Small Cell Lung Cancer Market Restraints
    Table 6. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Drugs for Non-Small Cell Lung Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Drugs for Non-Small Cell Lung Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Drugs for Non-Small Cell Lung Cancer Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Drugs for Non-Small Cell Lung Cancer Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Player, 2017-2022
    Table 13. Global Drugs for Non-Small Cell Lung Cancer Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Drugs for Non-Small Cell Lung Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2021)
    Table 15. Top Players of Drugs for Non-Small Cell Lung Cancer in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Drugs for Non-Small Cell Lung Cancer Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Drugs for Non-Small Cell Lung Cancer Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Drugs for Non-Small Cell Lung Cancer Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Drugs for Non-Small Cell Lung Cancer Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Drugs for Non-Small Cell Lung Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Drugs for Non-Small Cell Lung Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Drugs for Non-Small Cell Lung Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Bristol-Myers Squibb Company Details
    Table 31. Bristol-Myers Squibb Business Overview
    Table 32. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product
    Table 33. Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 34. Bristol-Myers Squibb Recent Development
    Table 35. GlaxoSmithKline Company Details
    Table 36. GlaxoSmithKline Business Overview
    Table 37. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product
    Table 38. GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 39. GlaxoSmithKline Recent Development
    Table 40. Menarini Company Details
    Table 41. Menarini Business Overview
    Table 42. Menarini Drugs for Non-Small Cell Lung Cancer Product
    Table 43. Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 44. Menarini Recent Development
    Table 45. Sanofi Company Details
    Table 46. Sanofi Business Overview
    Table 47. Sanofi Drugs for Non-Small Cell Lung Cancer Product
    Table 48. Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 49. Sanofi Recent Development
    Table 50. Ziopharm Oncology Company Details
    Table 51. Ziopharm Oncology Business Overview
    Table 52. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product
    Table 53. Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 54. Ziopharm Oncology Recent Development
    Table 55. Alchemia Company Details
    Table 56. Alchemia Business Overview
    Table 57. Alchemia Drugs for Non-Small Cell Lung Cancer Product
    Table 58. Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 59. Alchemia Recent Development
    Table 60. Amgen Company Details
    Table 61. Amgen Business Overview
    Table 62. Amgen Drugs for Non-Small Cell Lung Cancer Product
    Table 63. Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 64. Amgen Recent Development
    Table 65. Apotex Company Details
    Table 66. Apotex Business Overview
    Table 67. Apotex Drugs for Non-Small Cell Lung Cancer Product
    Table 68. Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 69. Apotex Recent Development
    Table 70. BioMarin Pharmaceutical Company Details
    Table 71. BioMarin Pharmaceutical Business Overview
    Table 72. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product
    Table 73. BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 74. BioMarin Pharmaceutical Recent Development
    Table 75. CellAct Pharma Company Details
    Table 76. CellAct Pharma Business Overview
    Table 77. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product
    Table 78. CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 79. CellAct Pharma Recent Development
    Table 80. Cerulean Pharma Company Details
    Table 81. Cerulean Pharma Business Overview
    Table 82. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product
    Table 83. Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 84. Cerulean Pharma Recent Development
    Table 85. Cipla Company Details
    Table 86. Cipla Business Overview
    Table 87. Cipla Drugs for Non-Small Cell Lung Cancer Product
    Table 88. Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 89. Cipla Recent Development
    Table 90. Cornerstone Pharmaceuticals Company Details
    Table 91. Cornerstone Pharmaceuticals Business Overview
    Table 92. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
    Table 93. Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 94. Cornerstone Pharmaceuticals Recent Development
    Table 95. Curis Company Details
    Table 96. Curis Business Overview
    Table 97. Curis Drugs for Non-Small Cell Lung Cancer Product
    Table 98. Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 99. Curis Recent Development
    Table 100. CytRx Company Details
    Table 101. CytRx Business Overview
    Table 102. CytRx Drugs for Non-Small Cell Lung Cancer Product
    Table 103. CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 104. CytRx Recent Development
    Table 105. Eli Lilly Company Details
    Table 106. Eli Lilly Business Overview
    Table 107. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product
    Table 108. Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 109. Eli Lilly Recent Development
    Table 110. Exelixis Company Details
    Table 111. Exelixis Business Overview
    Table 112. Exelixis Drugs for Non-Small Cell Lung Cancer Product
    Table 113. Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 114. Exelixis Recent Development
    Table 115. Fresenius Kabi Company Details
    Table 116. Fresenius Kabi Business Overview
    Table 117. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product
    Table 118. Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 119. Fresenius Kabi Recent Development
    Table 120. Genentech Company Details
    Table 121. Genentech Business Overview
    Table 122. Genentech Drugs for Non-Small Cell Lung Cancer Product
    Table 123. Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 124. Genentech Recent Development
    Table 125. Hikma Pharmaceuticals Company Details
    Table 126. Hikma Pharmaceuticals Business Overview
    Table 127. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
    Table 128. Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 129. Hikma Pharmaceuticals Recent Development
    Table 130. Hospira Company Details
    Table 131. Hospira Business Overview
    Table 132. Hospira Drugs for Non-Small Cell Lung Cancer Product
    Table 133. Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 134. Hospira Recent Development
    Table 135. Intas Pharmaceuticals Company Details
    Table 136. Intas Pharmaceuticals Business Overview
    Table 137. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
    Table 138. Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 139. Intas Pharmaceuticals Recent Development
    Table 140. Karyopharm Therapeutics Company Details
    Table 141. Karyopharm Therapeutics Business Overview
    Table 142. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product
    Table 143. Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 144. Karyopharm Therapeutics Recent Development
    Table 145. Kyowa Hakko Kirin Company Details
    Table 146. Kyowa Hakko Kirin Business Overview
    Table 147. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product
    Table 148. Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 149. Kyowa Hakko Kirin Recent Development
    Table 150. Ligand Pharmaceuticals Company Details
    Table 151. Ligand Pharmaceuticals Business Overview
    Table 152. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
    Table 153. Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
    Table 154. Ligand Pharmaceuticals Recent Development
    Table 155. Research Programs/Design for This Report
    Table 156. Key Data Information from Secondary Sources
    Table 157. Key Data Information from Primary Sources
List of Figures
    Figure 1. Drugs for Non-Small Cell Lung Cancer Product Picture
    Figure 2. Global Drugs for Non-Small Cell Lung Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Drugs for Non-Small Cell Lung Cancer Market Size 2017-2028 (US$ Million)
    Figure 4. United States Drugs for Non-Small Cell Lung Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Drugs for Non-Small Cell Lung Cancer Market Size 2017-2028 (US$ Million)
    Figure 6. United States Drugs for Non-Small Cell Lung Cancer Market Share in Global 2017-2028
    Figure 7. Drugs for Non-Small Cell Lung Cancer Report Years Considered
    Figure 8. Product Picture of Radiofrequency Ablation (RFA)
    Figure 9. Product Picture of Radiation Therapy
    Figure 10. Product Picture of Chemotherapy
    Figure 11. Product Picture of Targeted Therapies
    Figure 12. Product Picture of Immunotherapy
    Figure 13. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type in 2022 & 2028
    Figure 14. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
    Figure 16. United States Drugs for Non-Small Cell Lung Cancer Market Share by Type in 2022 & 2028
    Figure 17. United States Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
    Figure 19. Product Picture of Hospitals
    Figure 20. Product Picture of Clinics
    Figure 21. Product Picture of Other
    Figure 22. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application in 2022 & 2028
    Figure 23. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
    Figure 25. United States Drugs for Non-Small Cell Lung Cancer Market Share by Application in 2022 & 2028
    Figure 26. United States Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2028) & (US$ Million)
    Figure 27. United States Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
    Figure 28. North America Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. U.S. Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Canada Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Europe Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 32. Germany Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. France Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. U.K. Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Italy Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Russia Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 38. China Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Japan Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. South Korea Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. India Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Australia Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Taiwan Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Indonesia Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Thailand Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Malaysia Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Philippines Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Latin America Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Mexico Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Brazil Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Argentina Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Turkey Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. UAE Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 57. GlaxoSmithKline Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 58. Menarini Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 59. Sanofi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 60. Ziopharm Oncology Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 61. Alchemia Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 62. Amgen Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 63. Apotex Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 64. BioMarin Pharmaceutical Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 65. CellAct Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 66. Cerulean Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 67. Cipla Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 68. Cornerstone Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 69. Curis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 70. CytRx Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 71. Eli Lilly Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 72. Exelixis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 73. Fresenius Kabi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 74. Genentech Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 75. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 76. Hospira Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 77. Intas Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 78. Karyopharm Therapeutics Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 79. Kyowa Hakko Kirin Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 80. Ligand Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
    Figure 81. Bottom-up and Top-down Approaches for This Report
    Figure 82. Data Triangulation
    Figure 83. Key Executives Interviewed